| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total net revenue | 67,455 | 59,952 | 49,324 | 58,555 |
| Cost of sales | 38,477 | 56,664 | 49,741 | 39,823 |
| Research and development | 75,174 | 79,363 | 76,879 | 68,245 |
| Selling, general, and administrative | 34,555 | 37,699 | 43,925 | 39,553 |
| Depreciation and amortization | 9,007 | - | - | - |
| Restructuring charges | 5,143 | - | - | - |
| Total costs and expenses | 162,356 | 173,726 | 170,545 | 147,621 |
| Loss from operations | -94,901 | -113,774 | -121,221 | -89,066 |
| Interest and other income, net | 1,243 | 4,104 | 3,220 | 4,005 |
| Net loss before income taxes | -93,658 | -109,670 | -118,001 | -85,061 |
| Income tax (expense) benefit | -2,405 | 1,988 | -1,838 | -1,520 |
| Net loss | -91,253 | -111,658 | -116,163 | -83,541 |
| Earnings per share, diluted | - | -0.33 | -0.36 | -0.28 |
| Weighted average number of shares outstanding, diluted | - | 334,511 | 322,868 | 303,269 |
| Earnings per share, basic | -0.25 | -0.33 | -0.36 | -0.28 |
| Weighted average number of shares outstanding, basic | 364,037 | 334,511 | 322,868 | 303,269 |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)